EpimAb Files US/China INDs for Bispecific Cancer Antibody

21:39 EDT 14 Sep 2018 | ChinaBio Today

Shanghai's EpimAb Biotherapeutics filed US and China INDs simultaneously for a bispecific antibody that targets EGFR and cMET receptors. The company expects to test EMB01, its most advanced candidate, in patients with solid tumors. Founded three years ago, EpimAb uses its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) technology to generate bispecific molecules. It said EMB01 produced significant and long-lasting activity in several preclinical models of solid tumors. More details....

Share this with colleagues:

Original Article: EpimAb Files US/China INDs for Bispecific Cancer Antibody


More From BioPortfolio on "EpimAb Files US/China INDs for Bispecific Cancer Antibody"

Quick Search


Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...